Healthcare entity

Johns Hopkins University

Company

regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention America First Policy Institute, the most common co-covered peer. Johns Hopkins University appears in 1 tracked Healthcare story from August 20, 2026.

Last mentioned: 3d ago

Entity pulse

Recent coverage · Johns Hopkins University

1 story
7 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Johns Hopkins University

regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention America First Policy Institute, the most common co-covered peer. Johns Hopkins University appears in 1 tracked Healthcare story from August 20, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Johns Hopkins University. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Trump announces Heidi Overton as FDA Commissioner nominee

    President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.

  2. Marty Makary resigns as FDA Commissioner

    The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.

Stories mentioning Johns Hopkins University 1

Health Policy Neutral

Overton's FDA Pick: 3 Regulatory Fault Lines for Health Tech

For health IT, medical device and telehealth leaders, Overton's nomination signals a period of regulatory uncertainty. Her backing of MAHA and most favored nation drug pricing could reshape digital health evidence standards, diagnostics oversight and vaccine-adjacent software, even as deregulatory forces promise faster approvals. Confirmation will test how the FDA balances innovation with public health safeguards.

2 sources

Johns Hopkins University is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.